Oligonucleotide Conjugates for Enhanced Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nucleic acid therapy faces challenges such as poor intracellular uptake, limited blood stability, and non-specific immune stimulation, which hinder its effectiveness in drug target validation and disease therapeutics.
Innovation Solution
Development of oligonucleotide conjugates comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer, where the oligonucleotide is modified with compounds according to Formula (II) or (IIa), enhancing intracellular uptake, stability, and reducing toxicity and non-specific immune stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oligonucleotide therapy is administered, then gene expression can be modulated for therapeutic effect, but intracellular uptake is poor and blood stability is limited
Solution Approach 1:
The patent applies composite materials by creating oligonucleotide conjugates that combine a polynucleic acid molecule with a polymer component. This composite structure integrates the gene-silencing capability of oligonucleotides with the enhanced cellular uptake and stability properties of polymers, thereby improving both intracellular delivery and blood stability while maintaining therapeutic effectiveness
Solution Approach 2:
The patent uses a conjugate structure as an intermediary between the oligonucleotide therapy and cellular targets. The polymer component acts as a mediator that facilitates cellular uptake and protects the oligonucleotide from degradation in circulation, enabling effective drug delivery without direct administration of bare oligonucleotides
2Reliability
If oligonucleotide therapy is administered, then gene expression can be modulated, but non-specific immune stimulation occurs
Solution Approach 1:
The polymer component in the conjugate serves as a protective intermediary that shields the oligonucleotide from immune system recognition. This mediator reduces non-specific immune stimulation while allowing the oligonucleotide to maintain its gene-modulating function, thereby improving the safety profile of the therapy
3Reliability
If oligonucleotide therapy is administered, then gene suppression can be achieved, but blood stability is limited
Solution Approach 1:
The patent creates a composite conjugate structure where the polymer component provides enhanced stability in blood circulation. This composite design protects the oligonucleotide from nucleases and premature degradation, extending its half-life and stability in the bloodstream while maintaining its gene suppression capability upon cellular delivery
Data Source
AI summary
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.